



Note: screenshots are not all-inclusive as system user interface may vary depending on grant mechanism and application attributes. Some screenshots provided also represent mock-ups of system features currently under development (e.g., changes to C.5.c. as part of this revision request).


B. Accomplishments ?



Expand/Collapse All









Add Revision Supplement		×
Revision/Supplement #		
############		
or Revision/Supplement Title		
255 characters remaining		
Describe the specific aims for this Revision/Supplement below *		
700 characters remaining		
Describe the accomplishments for this Revision/Supplement below *		
700 share there are relations		10
700 characters remaining		
	Cancel	+ Add


✓ 3 B.3 Competitive Revisions/Administrative Supplements
For this reporting period, is there one or more Revision/Supplement associated with this award for which reporting is required? • Yes O No
If yes, identify the Revision(s)/Supplement(s) by grant number (e.g., 3R01CA098765-01S1) or title and describe the specific aims and accomplishments for each Revision/Supplement funded during this reporting period. Include any supplements to promote diversity or re-entry, or other similar supplements to support addition of an individual or a discrete project. + Add/New
✓ B.4 What opportunities for training and professional development has the project provided?
If the research is not intended to provide training and professional development opportunities or there is nothing significant to report during this reporting period, select "Nothing to Report."
Describe opportunities for training and professional development provided to anyone who worked on the project or anyone who was involved in the activities supported by the project. "Training" activities are those in which individuals with advanced professional skills and experience assist others in attaining greater proficiency. Training activities may include, for example, courses or one-on-one work with a mentor. "Professional development" activities result in increased knowledge or skill in one's area of expertise and may include workshops, conferences, seminars, study groups, and individual study. Include participation in conferences, workshops, and seminars not listed under major activities.
For all projects reporting graduate student and/or postdoctoral participants in Section D. Participant, grantees are encouraged to describe the use of Individual Development Plans (IDPs) for those participants. A Do not include the actual IDP; instead include information to document that IDPs are used to help manage the training for those individuals.
☐ Nothing to Report
Upload Description and Diversity Report, as applicable
,,
⚠ Drop files here to upload, or <u>browse.</u> Max File Count: 1 Accepted File Types: PDF Max File Size: 6MB
→ B.5 How have the results been disseminated to communities of interest?
Describe how the results have been disseminated to communities of interest. Include any outreach activities that have been undertaken to reach members of communities who are not usually aware of these research activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.
Reporting the routine dissemination of information (e.g., websites, press releases) is not required. For awards not designed to disseminate information to the public or conduct similar outreach activities, a response is not required and the grantee should select "Nothing to Report". A detailed response is only required for awards or award components that are designed to disseminate information to the public or conduct similar outreach activities. Note that scientific publications and the sharing of research sources will be reported under Products. Nothing to Report
or enter response below

dd Revision Supplement	
evision/Supplement #	
############	
r Revision/Supplement Title	
55 characters remaining	
escribe the specific aims for this Revision/Supplement below *	
0 characters remaining	
escribe the accomplishments for this Revision/Supplement belo	ow *
00 characters remaining	
0 characters remaining	Cancel + Add
	Cancel + Add
✓ B.6 What do you plan to do during the next reporting period to accomplish the goals?	
➤ B.6 What do you plan to do during the next reporting period to accomplish the goals? Describe briefly what you plan to do during the next reporting period to accomplish the goals and ③ Discuss efforts to ensure that the approach is scientifically rigorous and results are robust and un	objectives. Nobjectives abjectives in the significant changes in
➤ B.6 What do you plan to do during the next reporting period to accomplish the goals? Describe briefly what you plan to do during the next reporting period to accomplish the goals and ② Discuss efforts to ensure that the approach is scientifically rigorous and results are robust and ure objectives and scope require prior approval of the agency (e.g., NIH Grants Policy Statement, 8.1.2.) ③ Include any important modifications to the original plans. Provide a scientific justification for any	objectives. objased. Remember that significant changes in
✓ B.6 What do you plan to do during the next reporting period to accomplish the goals? Describe briefly what you plan to do during the next reporting period to accomplish the goals and ✓ Discuss efforts to ensure that the approach is scientifically rigorous and results are robust and urobjectives and scope require prior approval of the agency (e.g., NIH Grants Policy Statement, 8.1.2.) ✓ Include any important modifications to the original plans. Provide a scientific justification for any vertebrate animals. A detailed description of such changes must be provided under Changes.	objectives. objased. Remember that significant changes in
➤ B.6 What do you plan to do during the next reporting period to accomplish the goals? Describe briefly what you plan to do during the next reporting period to accomplish the goals and ② Discuss efforts to ensure that the approach is scientifically rigorous and results are robust and ur objectives and scope require prior approval of the agency (e.g., NIH Grants Policy Statement, 8.1.2.) ③ Include any important modifications to the original plans. Provide a scientific justification for any vertebrate animals. A detailed description of such changes must be provided under Changes. Enter response below Finish characterization and efficacy of DHED in a non-human primate model to prevent menopau	objectives. Ibiased. Remember that significant changes in changes involving research with human subjects or



✓ C.2 Website(s) or other Internet site(s)
List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above.
A description is only required for awards designed to create or maintain one or more websites. If the website disseminates a product that falls into other product categories, please select the appropriate category(ies) from the pull-down menu (select multiple categories by holding down the Ctrl button while selecting the categories). Limit the response to this reporting period. For awards not designed to create or maintain one or more websites, select "Nothing to Report".
□ Nothing to Report
or list URL(s) for Internet site(s) and provide description(s) below
+ New Web/Internet Site
✓ C.3 Technologies or techniques
Identify technologies or techniques that have resulted from the research activities. Describe the technologies or techniques and how they are being shared.
If the technology or technique falls into other product categories, please select the appropriate category(ies) from the pull-down menu (select multiple categories by holding down the Ctrl button while selecting the categories). If the product(s) has been reported or shared through a publication, please include the full reference and/or PubMed ID in the product description. Limit the response to this reporting period. If there are no technologies or techniques to report select "Nothing to Report"
☐ Nothing to Report
or list URL(s) for Internet site(s) and provide description(s) below
+ New Technology/Technique
✓
Have inventions, patent applications and/or licenses resulted from the award during this reporting period? Yes No
If yes, has this information been previously provided to the PHS or to the official responsible for patent matters at the grantee organization? Yes No
Reporting of inventions through <u>iEdison</u> is strongly encouraged.
✓ C.5 Other products and resource sharing
Identify any other significant products that were developed under this project.
PD/PIs are required to report all products that arise from their NIH award in section C. If there are other products to report not covered in Sections C1 - C4, enter a description for the product and choose the appropriate product category(ies) from the pull down menu (select multiple categories by holding down the Ctrl button while selecting the categories). If there is more than one product to report, select "add product" to create a workspace to report an additional product. Limit the response to this reporting period.
☐ Nothing to Report
or list URL(s) for Internet site(s) and provide description(s) below
+ New Product/Resource
Cancel • Save





Note: screenshots are not all-inclusive as system user interface may vary depending on grant mechanism and application attributes. Some screenshots provided also represent mock-ups of system features currently under development (e.g., changes to C.5.c. as part of this revision request).



C.5.b Resource Sharing

PD/PIs and recipient organizations are expected to make the results and accomplishments of their activities available to the research community and to the public at large. For additional information on NIH Sharing Policies and Related Guidance on NIH-Funded Research Resources see https://grants.nih.gov/grants/sharing.htm.

If the initial research plan addressed, or the terms of award require, a formal plan for sharing final research data, model organisms, Genome Wide Association Studies data, or other such project-specific data, describe the progress in implementing that plan. For sharing model organisms, include information on the number of requests received and number of requests fulfilled during this reporting period. If the sharing plan is fully implemented, provide a final statement on data sharing.

Nothing to Report

Progress implementing the resource sharing plan

ex:


8000 characters remaining


C.5. c Data Management and Sharing
Describe activities related to the approved Data Management and Sharing Plan. For each Data Type identified in the approved DMS Plan, provide the following information, as applicable:
Applicable Not Applicable +Add DMSP Information
*If data has not been generated and/or shared as outlined in the approved Plan, describe why, and identify any corrective actions that have or will be taken to comply with the approved plan.
Description
2000 characters remaining
Are significant prospective changes to the Data Management and Sharing Plan being requested for the coming year (e.g., change in repository, change in timeline, or change in scientific direction)? No Change
If yes, enter description of the change(s) and upload revised Data Management and Sharing Plan for approval. Enter description of change
2000 characters remaining
Upload revised Data Management and Sharing Plan
Drop files to attach, or <u>browse</u> .
Files should not exceed 6MB.


Note: screenshots are not all-inclusive as system user interface may vary depending on grant mechanism and application attributes. Some screenshots provided also represent mock-ups of system features currently under development (e.g., changes to C.5.c. as part of this revision request).

X

Data Management and Sharing Plan Information









@D.2 Personnel Update
✓ D.2.a Level of Effort
Will there be, in the next budget period, either 1. a reduction of 25% or more in the level of effort from what was approved by the agency for the PD/PI(s) or other senior/key personnel designated in the Notice of Award, or 2. a reduction in the level of effort below the minimum amount of effort required by the Notice of Award?
• Yes No Reductions are cumulative, i.e., the 25% threshold may be reached by two or more successive reductions that total 25% or more. Once agency approval has been given for a significant change in the level of effort, then all subsequent reductions are measured against the approved adjusted level. Selecting "yes" constitutes a prior approval request to the agency and the issuance of a subsequent year of funding constitutes agency approval of the request. If yes, provide an explanation below
700 characters remaining
∨ D.2.b New Senior/Key Personnel
Are there, or will there be, new senior/key personnel? \(\bar{\chick}\) Yes \(\chick\) No Senior/key personnel are those identified by the grantee institution as individuals who contribute in a substantive measurable way to the scientific development or execution of the project, whether or not salaries are requested. Typically these individuals have doctoral or other professional degrees, although individuals at the masters or baccalaureate level may be considered senior/key personnel if their involvement meets this definition. Consultants may be considered senior/key personnel if they meet this definition. "Zero percent" effort or "as needed" is not an acceptable level of involvement for senior/key personnel. If yes, upload biosketches and other support for all new senior/key personnel Please upload supporting document: \[\begin{array}{c} \text{Drop files here to upload, or \text{browse}.} \\ \text{Max File Count: 1 Accepted File Types: PDF Max File Size: 6MB} \end{array}
V D.2.c Changes in Other Support Has there been a change in the active other support of senior/key personnel since the last reporting period? Yes ○ No
If yes, upload active other support for senior/key personnel whose support has changed and indicate what the change has been
Please upload supporting document:
Max File Count: 1 Accepted File Types: PDF Max File Size: 10MB Combined_OS.pdf
✓ D.2.d New Other Significant Contributors
Are there, or will there be, new other significant contributors? • Yes No Other significant contributors are individuals who have committed to contribute to the scientific development or execution of the project, but are not committing any specified measurable effort (i.e., person months) to the project. If yes, upload biosketches for all new other significant contributors.
Please upload supporting document: Drop files here to upload, or <u>browse.</u> Max File Count: 1 Accepted File Types: PDF Max File Size: 6MB
∨ D.2.e Multi-Pl (MPl) Leadership Plan
Will there be a change in the MPI Leadership Plan for the next budget period? N/A • Yes No Change in status of PD/PI requires prior approval of the agency (e.g., NIH Grants Policy Statement, 8.1.2.6). If yes, upload a revised MPI Leadership Plan that includes a description of the change(s)
Please upload supporting document:


Note: screenshots are not all-inclusive as system user interface may vary depending on grant mechanism and application attributes. Some screenshots provided also represent mock-ups of system features currently under development (e.g., changes to C.5.c. as part of this revision request).




E. Impact 😯










✓ ③F.3 Significant changes to Human Subjects, Vertebrate Animals, Biohazards, and/or Select Agents
Describe significant deviations, unexpected outcomes, or changes in approved protocols for human subjects, vertebrate animals, biohazards, and/or select agents during this reporting period.
Remember that significant changes in objectives and scope require prior approval of the agency (e.g., NIH Grants Policy Statement, 8.1.2.). If there are changes in any of the following areas check the appropriate box and provide a description of the changes.
F.3.a Human Subjects
If human subject protocols are or will be different from the previous submission, include a description and explanation of how the protocols differ and provide a new or revised Protection of Human Subjects Section as described in the competing application instructions.
☐ Nothing to Report
or upload description of change
Drop files here to upload, or browse.
Max File Count: 1 Accepted File Types: PDF Max File Size: 6MB
F.3.b Vertebrate Animals
If there are or will be significant changes to the uses of vertebrate animals from the previous submission, provide a description of the changes. Examples of changes considered to be significant include, but are not limited to, changing animal species, changing from noninvasive to invasive procedures, new project/performance site(s) where animals will be used, etc. If studies involving live vertebrate animals are planned and were not part of the originally proposed research design, provide a new or revised Vertebrate Animal Section as described in the competing application instructions.
☐ Nothing to Report
or upload description of change
Drop files here to upload, or browse.
Max File Count: 1 Accepted File Types: PDF Max File Size: 6MB
×
F.3.c Biohazards
If the use of biohazards is or will be different from the previous submission, provide a description and explanation of the difference(s).
□ Nothing to Report
or upload description of change
♠ Drop files here to upload, or browse.
Max File Count: 1 Accepted File Types: PDF Max File Size: 6MB
`**************************************
F.3.d Select Agents
If the possession, use, or transfer of Select Agents is or will be different from that proposed in the previous submission, including any change in the select agent research location and/or the required level of biocontainment, provide a description and explanation of the differences. If the use of Select Agents was proposed in the previous submission but has not been approved by regulatory authorities, provide an explanation. If studies involving Select Agents are planned and were not part of the originally proposed research design, provide a description of the proposed use, possession, transfer, and research location as described in the competing application instructions. U.S. Select Agent Registry information
☐ Nothing to Report
or upload description of change
Drop files here to upload, or <u>browse</u> .
Max File Count: 1 Accepted File Types: PDF Max File Size: 6MB
×/








Project/Performance Sites	>
Required Fields *	
Organization Name *	Unique Entity Identifier (UEI) *
	ex: AB0CDEF1GHL2
Address Line 1 *	Address Line 2
City *	County
Country *	
Begin Typing and Select One	v
Zip Code *	
ex: 12345 or 123451234	
Primary Site	
	Cancel + Add Project/Performance Site








Note: screenshots are not all-inclusive as system user interface may vary depending on grant mechanism and application attributes. Some screenshots provided also represent mock-ups of system features currently under development (e.g., changes to C.5.c. as part of this revision request).





When Budget Forms are Required












Note: screenshots are not all-inclusive as system user interface may vary depending on grant mechanism and application attributes. Some screenshots provided also represent mock-ups of system features currently under development (e.g., changes to C.5.c. as part of this revision request).



Final/Interim-RPPR Outcomes


I. Outcomes 🔞

♣ Remember to save all your changes before leaving the page.
 ✔ For NIH Section I. Outcomes will be made publicly available, thus allowing recipients to provide the general public with a concise summary of the cumulative outcomes or findings of the project at the end of a competitive segment. For NIH awards the length should not exceed half a page. In addition, for the interim or final RPPR, the summary of outcomes or findings of the award must be written in the following format:

 Is written for the general public in clear, concise, and comprehensible language;
 Is suitable for dissemination to the general public, as the information may be available electronically;
 Does not include proprietary, confidential information or trade secrets

 Please refer to the following link for samples of acceptable project outcomes: C* https://grants.nih.gov/grants/rppr/sample project outcomes RPPR.htm">Let outcomes RPPR.htm

Expand/Collapse All




◆ Cancel • Save


A. Cover Page | B. Accomplishments | C. Products | D. Participants | E. Impact | G. Special Reporting Req | I. Outcomes

Note: screenshots are not all-inclusive as system user interface may vary depending on grant mechanism and application attributes. Some screenshots provided also represent mock-ups of system features currently under development (e.g., changes to C.5.c. as part of this revision request).

Complex/Multi-project RPPR Menu



Note: screenshots are not all-inclusive as system user interface may vary depending on grant mechanism and application attributes. Some screenshots provided also represent mock-ups of system features currently under development (e.g., changes to C.5.c. as part of this revision



Annual RPPR:

Public reporting burden for this collection of information is estimated to average 9 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. **An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.** Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0002). Do not return the completed form to this address.

Final RPPR:

Public reporting burden for this collection of information is estimated to average 11 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. **An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.** Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0002). Do not return the completed form to this address.